| Date | Title | Description |
| 16.09.2026 | Five percent stake in TrueFan AI acquired by Bajaj Finance | A 5% share in TrueFan AI, an AI-powered video creation platform, has been purchased by Bajaj Finance, a division of Bajaj Finserv.
In June of this year, the Gurugram-based business raised $10 million in a Series A fundraising round headed b... |
| 09.09.2026 | Bajaj Finance acquires 5% stake in AI video startup TrueFan AI | Bajaj Finance Limited has acquired a 5% stake in AI-powered video generation platform TrueFan AI as part of Bajaj Finserv’s Finserv Intelligence initiative, which focuses on investments and innovation in emerging technologies.
Advertisment
... |
| 29.08.2026 | Maharashtra FDA cancels Cipla’s Pune unit licence; company contests order | - |
| 29.08.2026 | Cipla Pharma license cancellation order withdrawn as HC chides Maharashtra FDA | - |
| 17.07.2026 | Notice of annual general meeting in EQL Pharma AB | Notice of annual general meeting in EQL Pharma AB
Fri, Jul 17, 2026 10:15 CET Report this content
The shareholders of EQL Pharma AB, Reg. No. 556713-3425, are hereby invited to the annual general meeting to be held on Thursday 20 August 202... |
| 04.06.2026 | TrueFan AI, Phab, KorinMi, The Sweet Change raise early-stage funding | TrueFan AI's founders Nimish Goel and Devender Bindal
AI video-generation startup TrueFan AI, protein snack brand Phab, Korean skincare clinic chain KorinMi, and natural sweetener startup The Sweet Change have raised fresh funding.
TrueFan ... |
| 13.05.2026 | Cipla bets on fast-growing biosimilars market, to steadily add products: CEO | Cipla is building a biosimilars pipeline, and aims to steadily add products over the next five years, its top executive said, as the company bets on the fast-growing market for cheaper versions of complex biologic drugs.
“We are advancing o... |
| 04.04.2026 | India’s pharma exports grow 5.6% to $28 billion in April–February FY26 | - |
| 08.03.2026 | Cipla recalls over 400 cartons of cancer drug in US: USFDA | - |
| 09.02.2026 | 'Made in India - The story of Desh Bandhu Gupta, Lupin and Indian Pharma' Book Launched in Mumbai | MUMBAI, India, Feb. 9, 2026 /PRNewswire/ -- Made in India, written by Sundeep Khanna and Manish Sabharwal, traces three remarkable journeys: the rise of India's pharma industry, the birth and evolution of Lupin (BSE: 500257) (NSE: LUPIN) (R... |
| 26.01.2026 | Sun Pharma, Cipla recall products in US market: USFDA | - |
| 23.01.2026 | Cipla Q3 net profit dips 57 per cent due to Lanreotide production halt | - |
| 05.01.2026 | Generic drugmakers eye ₹5,000 crore semaglutide opportunity, but exports pathway fraught with hurdles | - |
| 02.01.2026 | Cough syrup controversy: Segment sees a “cautious” shift by consumers and doctors, say industry -watchers | - |
| 22.12.2025 | Cipla launches ‘inhaled insulin’, a needle-free alternative for people with diabetes | - |
| 19.12.2025 | Cipla ties up with Pfizer for exclusive marketing of four brands | - |
| 08.12.2025 | EMCX 2025 Marks a Milestone Year for WebEngage as BLACK and CDPx Redefine the Future of Martech | Mumbai, Maharashtra, India
WebEngage, South Asia’s leading retention and customer engagement platform, concluded the final edition of EMCX 2025 in Gurugram, completing a high-impact three-city series that began in Mumbai and continued in Be... |
| 28.11.2025 | Cipla opens lung centre in Delhi | - |
| 13.11.2025 | Bora 3Q25 Delivers Renewed Profitability as Efficiency and Scale Improves | Strategic realignment powering Bora’s dual-engine businesses model
HONG KONG SAR – Media OutReach Newswire – 13 November 2025 – Bora Pharmaceuticals (TWSE: 6472) today announced its financial results and operational highlights for third qua... |
| 03.11.2025 | Cipla to buy Inzpera Healthsciences for ₹110 crore | - |
| 31.10.2025 | Health Biotech Strengthens Global Footprint at CPHI Frankfurt 2025 | New Delhi, Delhi, India
Health Biotech Limited (Health Biotech), a research and development-driven pharmaceutical company from India, successfully concluded its participation at CPHI Frankfurt 2025. Considered one of the most respected glob... |
| 30.10.2025 | Cipla Q2 results: Consolidated net profit rises 3.7% to ₹1,353 cr | - |
| 23.10.2025 | Cipla to market Eli Lilly’s weight loss and diabetes drug Mounjaro in India, under a different brand name | - |
| 07.10.2025 | Eli Lilly To Invest Over USD 1 Bn to Boost Manufacturing in India The company will also set up a new manufacturing and quality hub in Hyderabad. | Eli Lilly and Company, the US-based pharma major known for weight-loss drug Mounjaro, has announced plans to invest over USD 1 billion into contract manufacturing in India over the next several years.
The company will establish a new manufa... |
| 27.08.2025 | Cipla recalls over 20k packs of inhalation drug in US | - |
| 14.08.2025 | Zepto backer Ayra Ventures hires Sixth Sense exec to ramp up private market strategy | Premium
Samina Hamied, founder and managing partner, Ayra Ventures
Multi-asset investment firm Ayra Ventures, which was founded by Samina Hamied, former executive vice chairperson of Cipla and a member of its founding family, has beefed up ... |
| 06.08.2025 | TurboHire raises $6 M Series A funding from IvyCap Ventures | The IvyCap Ventures-led Series A fundraising round for TurboHire, an enterprise recruiting automation tool, has received $6 million.
In its pre-Series A round, which was headed by Pentathlon VC and The Chennai Angels, TurboHire had raised $... |
| 05.08.2025 | TurboHire gets $6M in Series A funding led by IvyCap Ventures | TurboHire, an AI-powered recruitment automation platform for enterprises, has secured $6 million in Series A funding led by IvyCap Ventures.
Founded in 2019 by Deepak Agrawal, Rakesh Nayak, and Gaurav Kumar, TurboHire is built around agenti... |
| 02.08.2025 | Why Waterfall and Midrand Are Gauteng’s Fastest-Growing Hubs for Warehousing, Logistics, and Health Innovation | Share
Share
Share
Share
Email
If you’ve been following commercial property trends in Gauteng recently, you’ll have noticed the significant growth happening in the Waterfall and Midrand corridors. Over the last few years, these two areas hav... |
| 25.07.2025 | Q1 Results Highlights: Shriram Finance Q1 profit up 9%, Bajaj Finserv, Bank of Baroda & Cipla profit increase, SBI Cards profit drops 6%, Sobha profit soars to ₹13.61 cr, SAIL Q1 net profit zooms ... | Business man or analyst in front of desktop computer holding a modern transparent tablet screen reviewing business performance and a return on investment, ROI, and investement risk analysis istock photo for BL | Photo Credit: ktasimarr
Q1 R... |
| 25.07.2025 | Health insurer Centene reports surprise quarterly loss | Health insurer Centene reports surprise quarterly loss
By ReutersJuly 25, 202510:08 AM UTCUpdated ago
Text
Small Text
Medium Text
Large Text
Share
X
Facebook
Linkedin
Email
Link
A sign for Wellcare, part of the Centene Corporation, is seen ... |
| 23.07.2025 | Modi’s visit puts global Britain to the test | As India surges ahead, Britain must define its global future and decide whether it wants to be a partner of consequence or a spectator of decline.
Prime Minister Narendra Modi’s much anticipated visit this week to the UK to sign a historic ... |
| 21.07.2025 | Cipla invests in medical devices company iCaltech Innovations | - |
| 13.07.2025 | Cipla gears up to enter weight management segment in India | - |
| 13.07.2025 | Cipla to enter into weight management segment in India, says MD Umang Vohra | - |
| 01.07.2025 | Sun Pharma, Mankind, Cipla Lead Recruitments at SGT University's Mega Job Fest: PharmaPICK 2.0 | Gurugram, Haryana, India
SGT University, Gurugram, a NAAC A+ accredited institution renowned for its industry-aligned academics and placement-focused initiatives, successfully hosted PharmaPICK 2.0, A Mega Job Fest 2025, at its vibrant camp... |
| 26.06.2025 | Indian companies' profit puzzle: When global turmoil meets economic theory | - |
| 19.06.2025 | How the world's top ad agencies aligned to fix prices in India | NEW DELHI :Omnicom Media's India chief was frustrated. It was October 5, 2023 and a rival was trying to poach the U.S. firm's client by offering lower prices, just weeks after global advertising agencies and broadcasters struck secret pacts... |
| 05.06.2025 | India gets major investment boost during Piyush Goyals Italy visit as top firms pledge expansion, increased commitments | - |
| 15.05.2025 | Waters Corp's India business boosted by rush for weight-loss drugs | Waters Corp's India business boosted by rush for weight-loss drugs
By Kashish TandonMay 15, 202511:48 AM UTCUpdated ago
Text
Small Text
Medium Text
Large Text
Share
X
Facebook
Linkedin
Email
Link
Boxes of Ozempic and Wegovy made by Novo Nor... |
| 13.05.2025 | US government order to have nil impact on Indian pharma players, says Cipla | - |
| 13.05.2025 | With several moving parts, next six months will be a challenge, says Cipla Chief Umang Vohra | - |
| 09.05.2025 | The Trade Tango: India and the U.S. Dance Towards a Deal | In the grand theater of global trade, India and the United States are poised for a significant performance. The stage is set, the audience is eager, but the choreography remains complex. India, often dubbed the “tariff king,” is now conside... |
| 08.05.2025 | CNBC’s Inside India newsletter: India looks ready for a deal with the U.S. — but at what cost? | Monday - Friday, 11:00 - 12:00 SIN/HK | 0500 - 06:00 CET
India, in fact, is among the countries nearing a trade deal with the U.S. Last week, Trump said that negotiations had been “coming along great ... we’ll have a deal with India.”
Recen... |
| 23.04.2025 | Endura Mass Becomes Official Weight Gainer Nutrition Partner for Lucknow Super Giants | Mumbai, Maharashtra, India
Endura Mass the leading weight gain supplement brand from Cipla Health has partnered with Lucknow Super Giants the franchise team of the Indian Premier League as their ‘Official Weight Gainer Nutrition partner.’ W... |
| 11.04.2025 | Cipla gets USFDA nod for generic cancer drug | - |
| 20.03.2025 | Eli Lilly’s weight-loss drug Mounjaro comes to India, eyes big market with increasing obesity and diabetes risk | Eli Lilly launched its blockbuster diabetes and weight-loss drug Mounjaro in India on Thursday, March 20, beating rival Novo Nordisk for a much-awaited entry into the world's most populous country grappling with high rates of obesity and di... |
| 20.03.2025 | Eli Lilly brings much-awaited weight-loss drug Mounjaro to India | The much-awaited weightloss and diabetes drug, Mounjaro from US-based Eli Lilly and Company will be available at local chemists in a few weeks, at an India-specific price.
Globally Mounjaro, and peers in this category, Ozempic/Wegovy from N... |
| 18.03.2025 | Cipla and Formosa sign multi-regional licensing deal for Clobetasol Suspension | This partnership aims to enhance ophthalmic care by providing better treatment for post-operative inflammation and pain in patients across 11 countries.
TAIPEI, March 18, 2025 /PRNewswire/ -- Taiwan-based Formosa Pharmaceuticals (6838.TW) t... |
| 19.02.2025 | Banking stocks lift Sensex, Nifty from early lows; broader markets stage a rebound | Trump announced on Tuesday his intention to impose 25 percent tariffs on auto, semiconductor, and pharmaceutical imports, a move that could disrupt international trade and send ripples across global markets.
Trade Watchlist Portfolio
Messag... |
| 17.02.2025 | Glenmark’s US plant to gain amid geopolitical shifts, says CMD | The evolving tariff situation in the US is “hard to predict”, Glenn Saldanha, Glenmark Pharma Chairman and Managing Director, told analysts. However, “given the geopolitical situation, we think Monroe should have a significant benefit, as w... |
| 29.01.2025 | Asia Book of Records Honors Cipla (Emerging Markets & Europe business unit) for Record-Breaking Doctor engagement on COPD Awareness Initiative | Cipla's (EMEU BU) 'Take Charge – I Pledge' campaign engaged 4,350 doctors across six countries, setting a new benchmark in raising COPD awareness.
MUMBAI, India, Jan. 29, 2025 /PRNewswire/ -- Cipla Limited (BSE: 500087) (NSE: CIPLA EQ) refe... |
| 21.12.2024 | Economic Crossroads: The RBI's Dilemma Amidst Growth and Inflation | The Reserve Bank of India (RBI) stands at a critical juncture. External Monetary Policy Committee (MPC) members are raising alarms. They see faltering growth and rising inflation as twin threats. Their voices echo a growing concern: the Ind... |
| 21.12.2024 | Bajaj Auto Charges Ahead with Electric Dreams | Bajaj Auto is revving up for a bold leap into the international market. The two-wheeler giant has unveiled its latest electric offering, the Chetak 35 series. This move marks a significant shift in the company’s strategy, aiming to export i... |
| 21.12.2024 | Bajaj Auto's Bold Leap into the Electric Future | Bajaj Auto is revving up for a new chapter. The two-wheeler giant is set to take its electric Chetak 35 series global by FY26. This move comes as the company aims to solidify its position in the booming electric vehicle (EV) market. The Che... |
| 20.12.2024 | Cipla faces ₹1 crore penalty imposed by GST Authority | Drugmaker Cipla said that a penalty of over ₹1 crore had been imposed on it by the GST Authority for an alleged inadmissable credit claim.
The company would file an appeal with the appellate authority, it said, adding that the development d... |
| 20.12.2024 | External MPC members call for rate cut flagging faltering growth, rising inflation | The Reserve Bank of India’s (RBI) external monetary policy committee (MPC) members—Nagesh Kumar and Ram Singh—voted for a 25 basis points (bps) repo rate cut citing faltering growth and rising inflation trajectory in the country, according ... |
| 20.12.2024 | Bajaj Auto to go international with EV Chetak 35 series | Two-wheeler maker Bajaj Auto aims to start exporting its electric Chetak in FY26. On Friday, the company launched the advanced Chetak 35 series starting at ₹1,20,000 (ex-showroom price) with a battery capacity of 3.5kWh.
Bajaj Auto, which h... |
| 11.12.2024 | Cipla to bring in inhaled insulin Afrezza from US’ MannKind Corporation | Drugmaker Cipla has got regulatory approval to market Afrezza, a rapid acting insulin delivered through an inhaler, as compared to other insulins given through injections.
The Central Drugs Standard Control Organisation (CDSCO) has given Ci... |
| 05.12.2024 | Cipla's Rollercoaster Ride: ESG Ratings and GST Penalties | Cipla Limited, a major player in the pharmaceutical industry, finds itself in a whirlwind of scrutiny and accolades. Recently, the company received an unsolicited Environmental, Social, and Governance (ESG) rating of B+ from SES Research. T... |
| 04.12.2024 | Cipla charged with ₹10.95 crore GST penalty by Jaipur tax authorities | The shares of Cipla Limited were trading at ₹1.5 lakh down by ₹21.85 or 1.42 per cent on the NSE today at 11 am.
Pharmaceutical major Cipla disclosed a significant GST penalty order from the Principal Commissioner of Central GST Commissione... |
| 02.12.2024 | Cipla receives unsolicited ESG rating of B+ from SES Research | The shares of Cipla Limited were trading at ₹1,524.20 down by ₹9.70 or 0.63 per cent on the NSE today at 11.10 am,
Pharmaceutical major Cipla Limited has been assigned an Environmental, Social, and Governance (ESG) score of 70.2 (Grade B+) ... |
| 11.11.2024 | A guide to understanding NIFTY indices in India | Share
Tweet
Share
Share
Email
When it comes to investing in the Indian securities market, most retail and institutional investors look closely at the performance of the Nifty indices. The Nifty indices have become synonymous with the overal... |
| 08.11.2024 | Lupin aims to be part of ‘first wave of generics’ on GLP-1 products: Nilesh Gupta | Drugmaker Lupin aims to be part of the first wave of generic drugmakers to make GLP-1 receptor agonists products, used to treat Type II diabetes and obesity, Lupin top-brass said.
This segment of products includes semaglutide, the internati... |
| 04.11.2024 | Laurus Labs steps up focus on R&D, lines up 62 products | Laurus Labs is augmenting it’s Research & Development (R&D) capabilities and is currently working on a significant number of new products.
According to Satyanarayana Chava, Founder and Chief Executive Officer, Laurus Labs, the compa... |
| 22.10.2024 | Ranjan Pai, Cipla Family In Fray To Bet On Zepto | SUMMARY
As per ET, with this fundraise, the company is seeking to shore up domestic shareholding with “well-known and credible” names
Zepto’s latest fundraise of up to $150 Mn is expected to close by the end of this month
In August, Zepto c... |
| 19.09.2024 | Cipla Health weighs controlling stake in PE-backed nutrition brand | Premium
Credit: Reuters
Cipla Health Ltd, the wholly-owned subsidiary and consumer healthcare arm of Cipla, is evaluating a majority stake purchase in a private equity-backed nutrition brand as part of the parent company's focus on ... |
| 12.09.2024 | Qualifyze: Life Sciences Supplier Risk Management Company Raises $54 Million (Series B) | Qualifyze, a supplier risk management company in the Life Sciences industry, announced $54 million in Series B funding from Insight Partners. Existing investors HV Capital, HarbourVest Partners, H14, and Cherry Ventures also participated.
W... |
| 10.09.2024 | Qualifyze Raises $54M in Series B Funding | Qualifyze, a Frankfurt, Germany-based company which specializes in supply chain risk management in the Life Sciences industry, raised $54M in Series B funding.
The round was led by Insight Partners, with participation from existing investor... |
| 30.08.2024 | Nifty logs gains for record 12th straight session, Sensex up 230 pts as pharma, realty stocks rally | Cipla, Bajaj Finance, Divis Labs, M&M, and Bajaj Finserv were the top gainers on the Nifty.
Benchmark indices Nifty and Sensex held steady in positive territory to end the day at record closing on August 30, driven by a sharp rally in r... |
| 22.08.2024 | Mid-day Mood | Nifty, Sensex hold firm as PSU Banks, FMCG stocks shine; VIX eases 2% | The India VIX, a measure of market anxiety, declined slightly by over 2 percent, settling at 13.
Benchmark indices NSE Nifty 50 and Sensex managed to hold on to gains following a strong start to trading on August 22 as positive global cues ... |
| 28.07.2024 | Cipla expects to commence supplies to US from China plant later this year | Drug major Cipla expects to commence supplies to the US market from its China facility in the second half of the current fiscal after getting approval from the American health regulator, according to its MD and global CEO Umang Vohra.
Addre... |
| 25.07.2024 | The Intersection of Employment History and Financial Opportunities**
** | ** In the world of finance, your employment history is more than just a line on your resume. It’s a key that unlocks doors to credit cards, loans, and financial stability. Think of it as a bridge connecting your past work experience to your... |
| 25.07.2024 | Market Pulse: A Cautious Dance on Dalal Street Amid Earnings and Economic Signals**
** | ** The Indian stock market is a living organism, pulsating with energy and uncertainty. As we approach a critical juncture—the Union Budget 2024—investors are treading carefully. The recent sell-off has left the benchmark indices gasping fo... |
| 25.07.2024 | Large cap funds: A suitable investment option in a growing India | Pune, Maharashtra, India
Equity investments offer significant growth potential in the long-term, but the associated risks can make investors apprehensive. Large cap mutual funds present a unique opportunity to investors to access the wealth... |
| 21.07.2024 | Dalal Street Week Ahead: Union Budget, Q1 Earnings, US GDP among 10 key factors to watch | Dalal Street Week Ahead
Market participants remain cautious ahead of the key event, the Union Budget 2024, scheduled for next week. The benchmark indices lost about a percent due to Friday's sell-off, ending the week flat with a positive bi... |
| 11.07.2024 | Five Industries Set to Revolutionize in India Utilizing AI and Deep Tech AI and Deep Tech are experiencing a huge surge in the Indian market, surpassing the e-commerce boom of the mid-2010s | Some years ago, Artificial Intelligence (AI) and Deep Tech were part of fantasy movies and we never imagined using them in our daily lives. But if you look at the recent data from Indian industries, you will be surprised to see that several... |
| 05.07.2024 | Cipla is now completely professionalised, says MD and Global CEO Umang Vohra | Cipla has “completely professionalised” over the last 10 years, said Cipla Managing Director and Global Chief Executive Umang Vohra, of a transformative journey undertaken even as two of its key promoters who built the business do not inten... |
| 24.06.2024 | Sun Pharma completes merger of Taro | Drugmaker Sun Pharmaceutical Industries has completed the merger of Israel’s Taro Pharmaceutical Industries, ending a long drawn-out feud between the two companies, that played out across multiple geographies.
Also read:Cipla, Sun Pharma in... |
| 21.06.2024 | Weight-loss-drug frenzy lures rich Indians to brave the gray market | - |
| 21.06.2024 | Cipla, Sun Pharma ink non-exclusive agreement with Takeda on acid-reflux drug | Drugmakers Cipla and Sun Pharma have signed non-exclusive patent license agreements with Takeda Pharmaceutical Company Limited, respectively, for ‘Vonoprazan’ for India. The drug is used to treat acid-related illnesses among patients.
Cipla... |
| 30.05.2024 | Why did investors dump Marksans Pharma shares post Q4 results? Know here | - |
| 29.05.2024 | Health secy highlights India's achievements, future goals at WHO assembly | - |
| 27.05.2024 | Indian pharmaceutical companies likely to cash in on US drug shortages | - |
| 24.05.2024 | Weak Q4 due to lower growth may be rare bitter pill for Sun Pharma | - |
| 22.05.2024 | Buy ideas for May 22: Britannia, Cipla; check target prices | - |
| 22.05.2024 | Cipla receives USFDA approval to market Lanreotide injection in US | - |
| 22.05.2024 | Cipla receives final approval for the generic version of Somatuline® Depot (Lanreotide) Injection 120 mg/ 0.5 mL, 90 mg/0.3 mL, 60 mg/0.2 mL | MUMBAI, India and WARREN, N.J., May 22, 2024 /PRNewswire/ -- Cipla Limited (BSE: 500087; NSE: CIPLA EQ; and hereafter referred to as "Cipla") and its wholly owned subsidiary Cipla USA Inc., (hereafter referred to as "Cipla&qu... |
| 22.05.2024 | Cipla rallies 4% on US FDA approval to market Lanreotide injection | - |
| 21.05.2024 | India on cusp of long-awaited economic take-off: RBI monthly bulletin | - |
| 21.05.2024 | Expect formulations biz to outpace API biz: Biocon Group CEO Peter Bains | - |
| 17.05.2024 | Indian pharma firms supplied 47% of all generic prescriptions in US in 2022 | - |
| 16.05.2024 | Cipla promoters sell 2.53% stake worth Rs 2,637 cr to fund philanthropy | - |
| 15.05.2024 | Cipla zooms 5% on 2.53% stake sale by Hamied family, Okasa Pharma | - |
| 15.05.2024 | Promoter group to sell 2.53% stake worth $316 million in Cipla: Report | - |
| 15.05.2024 | Cipla promoters sell 2.5% stake; Picked up by global, domestic funds | Drugmaker Cipla promoters sold over 2 crore shares in the company or 2.53 per cent of its equity in a block deal at a price of ₹1,345 for a total aggregate of ₹2,690 crore. The shares were picked up by a host of global and domestic funds, e... |
| 15.05.2024 | Bharti Airtel, Cipla, Paytm, Colgate among seven stocks to track on May 15 | - |
| 14.05.2024 | Cipla: Timely new launches, India outperformance key for margin gains | - |
| 14.05.2024 | Cipla promoters to sell up to 2.5% stake for ₹2637 crore | Pharma major Cipla’s promoters and promoter group entities are looking to sell up to 2.53 per cent stake in the company through a block deal for a total value of ₹2,637 crore, sources said.
The deal value is calculated at the floor price wi... |
| 13.05.2024 | Sensex, Nifty close higher after falling 1% intraday; analysts say 'exercise caution' | Broader markets mixed
Trade Watchlist Portfolio
Message
Set Alert
livebselivenselive
Volume
Todays L/H
More
×
The Sensex and Nifty 50 fully recovered from the day's lows on May 13 and closed in green after falling almost 1 percent each in t... |
